LivaNova Launches Essenz Perfusion System to Advance Cardiac Surgery Care

Published: 20 Aug 2025

Author: Precedence Research

Share :

LivaNova PLC, a leading global medical technology developer and manufacturer, has taken this critical step in launching the Essenz Perfusion System in China. The first stage in commercially launching this lifesaving technology in China. With the latest provision of NMPA in China, the availability of Essenz in the second-largest field of heart-lung machines (HLMs) globally, after the United States market, is now possible. It brings a new age of patient-customized perfusion, by using next-generation hardware, real-time monitoring, and machine intelligence to optimize clinical practice and patient outcomes during life-saving cardiopulmonary bypass (CPB) surgeries.

This launch is noteworthy as cardiovascular disease is an increasingly heavy burden in China. The Essenz Perfusion System is more than just an incremental advancement of the technologies LivaNova currently has, and more of a transformational platform that has been developed in conjunction with the global perfusionist community. The perfusionists with more than 300 professionals provided their experience during the design and testing to ensure that the system could bridge the gap between research and the operating room. Furthermore, it produces an improved next-generation solution that offers improved ergonomics, exactness, and management, with patient safety at the heart.

The machine is able to integrate three advanced units, such as the Essenz Heart-Lung Machine (HLM), the Essenz Patient Monitor, and the Essenz In-Line Blood Monitor (ILBM). They serve as complete solutions to enable perfusionists with real-time data visualization, precise blood monitoring, and simplified control throughout surgery. The modular design, in the same way, makes the monitor and HLM independent of each other, hence there is greater flexibility in varied clinical settings. Additionally, this technology allows constant updates and space to integrate and remain relevant in the changing surgical surroundings.

Executive Statements:

Franco Poletti, President, Cardiopulmonary, LivaNova:

“LivaNova has been working closely with top experts in China for years to promote the development of advanced extracorporeal circulation technology and therapy. Introducing Essenz to the Chinese market is an exciting step that will provide perfusionists and surgeons with enhanced safety and control during life-saving procedures, deliver better results for patients, and enhance the overall standard of care throughout the country.